《復牌表現》大成生化(00809.HK)配股籌1.28億股價續漲22%曾創近兩年半高
上周五中途停牌的大成生化科技(00809.HK)公布,以每股10仙(較停牌前折讓18.7%)向獨立第三方匯港投資發行12.8億股新股或佔擴大後股本16.67%,所得款項1.28億元將用作一般營運資金。
該股承上周五中途停牌前漲近9%勢,今早復牌曾突破4月所創52周高位0.16元,最多急漲54%高見0.19元,創近兩年半高遇阻,現造0.15元,續漲22%,成交增至7,395萬股,涉資1,244萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.